Vertex Pharmaceuticals Inc (VRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $136.56B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vertex Pharmaceuticals Inc (VRTX) Earnings: Report Dates and Results
Vertex Pharmaceuticals (VRTX) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Vertex Pharmaceuticals reported EPS of $4.21, below the $4.36 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VRTX has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.7% below the $5.03 reported for the quarter ended Dec 31, 2025.
VRTX Earnings Call
The latest VRTX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, VRTX beat 33 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $3.44B, up 11.7% from $3.08B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $4.21 | $4.36 | $3.79 - $5.25 | -3.44% | Miss | -12.3% | 13 | 5 up, 1 down | Nov 2, 2026 | $3.44B |
| Jun 30, 2026 | $4.20 | $4.15 | N/A | +1.20% | Beat | -7.1% | 23 | 9 up, 9 down | Aug 3, 2026 | $3.33B |
| Mar 31, 2026 | $4.47 | $4.31 | $3.67 - $4.86 | +3.81% | Beat | +10.1% | 24 | 2 up, 10 down | May 4, 2026 | $2.99B |
| Dec 31, 2025 | $5.03 | $5.15 | $4.46 - $5.71 | -2.33% | Miss | +26.4% | 22 | 3 up, 4 down | Feb 12, 2026 | $3.19B |
| Sep 30, 2025 | $4.80 | $4.58 | $4.20 - $5.01 | +4.80% | Beat | +9.6% | 22 | 4 up, 7 down | Nov 3, 2025 | $3.08B |
| Jun 30, 2025 | $4.52 | $4.25 | $3.92 - $4.63 | +6.35% | Beat | N/A | 23 | 1 up, 9 down | Aug 4, 2025 | $2.96B |
| Mar 31, 2025 | $4.06 | $4.29 | $3.95 - $5.19 | -5.36% | Miss | -14.7% | 21 | 3 up, 6 down | May 5, 2025 | $2.77B |
| Dec 31, 2024 | $3.98 | $4.02 | $3.41 - $4.85 | -0.99% | Miss | -5.2% | 25 | 4 up, 3 down | Feb 10, 2025 | $2.91B |
| Sep 30, 2024 | $4.38 | $4.13 | $3.77 - $4.90 | +6.05% | Beat | +7.4% | 22 | 4 up, 1 down | Nov 4, 2024 | $2.77B |
| Jun 30, 2024 | -$12.83 | -$11.75 | N/A | -9.19% | Miss | -429.8% | 10 | 1 up, 2 down | Aug 1, 2024 | $2.65B |
| Mar 31, 2024 | $4.76 | $4.06 | $3.61 - $4.44 | +17.24% | Beat | +56.1% | 21 | 6 up, 1 down | May 6, 2024 | $2.69B |
| Dec 31, 2023 | $4.20 | $4.09 | $3.83 - $4.43 | +2.69% | Beat | +11.7% | 21 | 7 up, 3 down | Feb 5, 2024 | $2.52B |
| Sep 30, 2023 | $4.08 | $3.97 | $3.34 - $4.39 | +2.77% | Beat | +1.7% | 22 | 3 up, 1 down | Nov 6, 2023 | $2.48B |
| Jun 30, 2023 | $3.89 | $3.88 | $3.47 - $4.25 | +0.26% | Beat | +8.1% | 22 | 3 up, 1 down | Aug 1, 2023 | $2.49B |
| Mar 31, 2023 | $3.05 | $3.00 | $2.63 - $3.67 | +1.67% | Beat | -13.4% | 20 | 2 up, 0 down | May 1, 2023 | $2.37B |
| Dec 31, 2022 | $3.76 | $3.51 | $2.73 - $3.90 | +7.12% | Beat | +11.6% | 20 | 3 up, 1 down | Feb 7, 2023 | $2.30B |
| Sep 30, 2022 | $4.01 | $3.64 | $3.16 - $4.06 | +10.16% | Beat | +12.6% | 20 | 2 up, 2 down | Oct 27, 2022 | $2.33B |
| Jun 30, 2022 | $3.60 | $3.50 | N/A | +2.86% | Beat | +15.8% | N/A | 1 up, 2 down | Aug 4, 2022 | $2.20B |
| Mar 31, 2022 | $3.52 | $3.54 | $2.79 - $3.82 | -0.56% | Miss | +18.1% | 18 | 1 up, 0 down | May 5, 2022 | $2.10B |
| Dec 31, 2021 | $3.37 | $3.29 | $3.03 - $3.70 | +2.43% | Beat | +34.3% | 19 | 1 up, 0 down | Jan 26, 2022 | $2.07B |
| Sep 30, 2021 | $3.56 | $3.07 | $2.70 - $3.45 | +15.96% | Beat | +34.8% | 18 | N/A | Nov 2, 2021 | $1.98B |
| Jun 30, 2021 | $3.11 | $2.38 | -$0.41 - $3.63 | +30.67% | Beat | +19.2% | 20 | N/A | Jul 29, 2021 | $1.79B |
| Mar 31, 2021 | $2.98 | $2.69 | $2.04 - $3.06 | +10.78% | Beat | +16.4% | 19 | N/A | Apr 29, 2021 | $1.72B |
| Dec 31, 2020 | $2.51 | $2.55 | $1.84 - $3.12 | -1.57% | Miss | +47.6% | 23 | N/A | Feb 1, 2021 | $1.63B |
| Sep 30, 2020 | $2.64 | $2.33 | $1.87 - $2.81 | +13.30% | Beat | +114.6% | 19 | N/A | Oct 29, 2020 | $1.54B |
| Jun 30, 2020 | $2.61 | $2.08 | $1.51 - $2.52 | +25.48% | Beat | +107.1% | 21 | N/A | Jul 30, 2020 | $1.52B |
| Mar 31, 2020 | $2.56 | $1.85 | $1.45 - $2.15 | +38.38% | Beat | +124.6% | 21 | N/A | Apr 29, 2020 | $1.52B |
| Dec 31, 2019 | $1.70 | $1.22 | $1.02 - $1.37 | +39.34% | Beat | +30.8% | 21 | N/A | Jan 30, 2020 | $1.41B |
| Sep 30, 2019 | $1.23 | $1.16 | $0.90 - $1.34 | +6.03% | Beat | +12.8% | 21 | N/A | Oct 30, 2019 | $949.83M |
| Jun 30, 2019 | $1.26 | $1.07 | $0.98 - $1.24 | +17.76% | Beat | +34.0% | 20 | N/A | Jul 31, 2019 | $941.29M |
| Mar 31, 2019 | $1.14 | $1.01 | $0.58 - $1.09 | +12.87% | Beat | +50.0% | 20 | N/A | Apr 30, 2019 | $858.43M |
| Dec 31, 2018 | $1.30 | $1.06 | $0.68 - $1.26 | +22.64% | Beat | +113.1% | 22 | N/A | Feb 5, 2019 | $87.59M |
| Sep 30, 2018 | $1.09 | $1.01 | $0.88 - $1.13 | +7.92% | Beat | +105.7% | 22 | N/A | Oct 24, 2018 | $1.57B |
| Jun 30, 2018 | $0.94 | $0.75 | $0.57 - $0.85 | +25.33% | Beat | +141.0% | 20 | N/A | Jul 25, 2018 | $752.16M |
| Mar 31, 2018 | $0.76 | $0.63 | $0.44 - $0.77 | +20.63% | Beat | -42.9% | 22 | N/A | Apr 26, 2018 | $640.80M |
| Dec 31, 2017 | $0.61 | $0.54 | $0.00 - $0.91 | +12.96% | Beat | +74.3% | 23 | N/A | Jan 31, 2018 | $651.63M |
| Sep 30, 2017 | $0.53 | $0.37 | -$0.35 - $0.51 | +43.24% | Beat | +231.3% | 23 | N/A | Oct 25, 2017 | $578.16M |
| Jun 30, 2017 | $0.39 | $0.36 | $0.22 - $0.41 | +8.33% | Beat | +62.5% | 19 | N/A | Jul 26, 2017 | $544.13M |
| Mar 31, 2017 | $1.33 | $1.05 | N/A | +26.67% | Beat | +1377.8% | N/A | N/A | Apr 27, 2017 | $714.72M |
| Dec 31, 2016 | $0.35 | $0.29 | N/A | +20.69% | Beat | +105.9% | N/A | N/A | Jan 25, 2017 | $458.71M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $18.41, up 6248.3% from the year before. It was $0.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $18.41 | +6248.3% |
| Dec 31, 2024 | $0.29 | -98.1% |
| Dec 31, 2023 | $15.22 | +2.2% |
| Dec 31, 2022 | $14.89 | +14.4% |
| Dec 31, 2021 | $13.02 | +26.2% |
| Dec 31, 2020 | $10.32 | +93.6% |
| Dec 31, 2019 | $5.33 | +30.3% |
| Dec 31, 2018 | $4.09 | +43.0% |
| Dec 31, 2017 | $2.86 | +240.5% |
| Dec 31, 2016 | $0.84 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,461 | 16 | |
| 2026Q2 | Jun 30, 2026 | 8,831 | 17 | |
| 2026Q1 | Mar 31, 2026 | 9,155 | 16 | |
| 2025Q4 | Dec 31, 2025 | 8,289 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,178 | 16 | |
| 2025Q2 | Jun 30, 2025 | 8,322 | 16 | |
| 2025Q1 | Mar 31, 2025 | 8,676 | 16 | |
| 2024Q4 | Dec 31, 2024 | 8,993 | 17 |
2026Q3 Earnings Call
Opening remarks
Susie Lisa Senior Vice President of Investor Relations Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our third quarter 2026 financial results conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Charles Wagner, Chief Operating Officer and Chief Financial Officer; and Duncan McKechnie, Chief Commercial Officer. Given Charles's January 1 transition to the COO role solely, please note that this is his last quarterly earnings call, and his successor, Jonathan Pool, our current SVP of Finance, will join us for our Q4 2026 call in February. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation, those regarding our marketed medicines for cystic fibrosis, sickle cell disease, beta thalassemia, moderate to severe acute pain, and acromegaly; our pipeline; the recently completed acquisition of Crinetics Pharmaceuticals and the expected benefits of that transaction; and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. I will now turn the call over to Reshma.
Reshma Kewalramani CEO and President Thanks, Susie. Good evening, all, and thank you for joining us on the call today. I am pleased to note that Vertex achieved another quarter of excellent commercial results and pipeline advancement. Third-quarter total revenue grew 12% year on year. Revenue growth was nicely balanced, coming from both the U.S. and international markets, from CF, and from our two more recently launched medicines, CASGEVY and JOURNAVX, as well as a contribution from PALSONIFY for the month of September following the close of the Crinetics acquisition. Rare endocrine is now our fourth commercial pillar. With the PDUFA date later this month for povetacicept in immunoglobulin A nephropathy, or IgAN, we plan to soon establish our fifth pillar in renal. Before turning to the R&D update, I want to acknowledge Charles's final—and 31st—earnings call as CFO. Charles's leadership, integrity, judgment, and intellectual rigor are unparalleled. He has deftly helped lead our transition from a CF-only company with $4 billion in revenue in 2019 to a company soon to be commercialized in five disease areas, with more than triple the revenue, with our guidance for over $13 billion in 2026.
Frequently Asked Questions About VRTX
When is Vertex Pharmaceuticals's next earnings date?
Vertex Pharmaceuticals's next earnings report is expected for Feb 10, 2027.
Did VRTX beat earnings estimates last quarter?
No. Vertex Pharmaceuticals reported EPS of $4.21 for the quarter ended Sep 30, 2026, below the $4.36 estimate by 3.44%.
What EPS do analysts expect from VRTX next quarter?
The consensus EPS estimate for Vertex Pharmaceuticals for the quarter ending Dec 31, 2026 is $4.19 from 30 analysts, with estimates from $3.71 to $5.32.
How often does VRTX beat earnings estimates?
Vertex Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +0.51%.
VRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors